Immuno-positron emission tomography: Shedding light on clinical antibody therapy

Cancer Biotherapy and Radiopharmaceuticals

Volumn 25, Issue 4, 2010, Pages 375-385

  Van Dongen, Guus A M S ^a,b   Vosjan, Maria J W D ^a  

^a VU UNIVERSITY AMSTERDAM   (Netherlands)

^b VU UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

immuno PET; iodine 124; monoclonal antibodies; zirconium 89

Indexed keywords

ALEMTUZUMAB; BEVACIZUMAB; CETUXIMAB; GEMTUZUMAB OZOGAMICIN; IBRITUMOMAB TIUXETAN; IODINE 124; MONOCLONAL ANTIBODY; MYELOTARG; PANITUMUMAB; RITUXIMAB; TOSITUMOMAB I 131; TRASTUZUMAB; UNCLASSIFIED DRUG; ZIRCONIUM; ZIRCONIUM 89;

ACUTE GRANULOCYTIC LEUKEMIA; BREAST CANCER; CANCER CHEMOTHERAPY; CANCER IMMUNOTHERAPY; CANCER RADIOTHERAPY; CHRONIC LYMPHATIC LEUKEMIA; COLORECTAL CANCER; COMPUTER ASSISTED TOMOGRAPHY; DIAGNOSTIC IMAGING; DRUG EFFICACY; HEAD AND NECK CANCER; HUMAN; IMAGE QUALITY; IN VIVO STUDY; ISOTOPE LABELING; LUNG NON SMALL CELL CANCER; LYMPHOMA; NONHODGKIN LYMPHOMA; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; REVIEW;

ANIMALS; ANTIBODIES, MONOCLONAL; CLINICAL TRIALS AS TOPIC; HEAD AND NECK NEOPLASMS; HUMANS; POSITRON-EMISSION TOMOGRAPHY; RADIOIMMUNOTHERAPY; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 77956143094     PISSN: 10849785     EISSN: None     Source Type: Journal    
DOI: 10.1089/cbr.2010.0812     Document Type: Review

References (78)

1. Hanahan D, Weinberg RA. The hallmarks of cancer. Cell 2000;100:57.
2. Reichert JM, Valge-Archer VE. Development trends for monoclonal antibody cancer therapeutics. Nat Rev Drug Discov 2007;6:349.
3. Reichert JM. Monoclonal antibodies as innovative therapeutics. Curr Pharm Biotechnol 2008;9:423.
4. Maggon K. Monoclonal antibody "gold rush." Curr Med Chem 2007;14:1978.
5. Lawrence S. Billion dollar babies-biotech drugs as blockbusters. Nat Biotechnol 2007;25:380.
6. Nelson AL, Reichert JM. Development trends for therapeutic antibody fragments. Nat Biotechnol 2009;27:331.
7. Mano M. The burden of scientific progress: Growing inequalities in the delivery of cancer care. Acta Oncol 2006; 45:84.
8. Neyt M, Albrecht J, Cocquyt V. An economic evaluation of Herceptin in adjuvant setting: The Breast Cancer International Research Group 006 trial. Ann Oncol 2006;17:381.
9. Kohler G, Milstein C. Continuous cultures of fused cells secreting antibody of predefined specificity. Nature 1975; 256:495.
10. Khazaeli MB, Conry RM, LoBuglio AF. Human immune response to monoclonal antibodies. J Immunother Emphasis Tumor Immunol 1994;15:42.
11. DeNardo GL, Bradt BM, Mirick GR, et al. Human antiglobulin response to foreign antibodies: Therapeutic benefit? Cancer Immunol Immunother 2003;52:309.
12. Bird RE, Hardman KD, Jacobson JW, et al. Single-chain antigen-binding proteins. Science 1988;242:423.
13. Ward ES, Gussow D, Griffiths AD, et al. Binding activities of a repertoire of single immunoglobulin variable domains secreted from Escherichia coli. Nature 1989;341:544.
14. Nord K, Gunneriusson E, Ringdahl J, et al. Binding proteins selected from combinatorial libraries of an alpha-helical bacterial receptor domain. Nat Biotechnol 1997;15:772.
15. Roovers RC, van Dongen GAMS, van Bergen en Henegouwen PMP. Nanobodies in therapeutic applications. Curr Opin Mol Ther 2007;9:327.
16. Beste G, Schmidt FS, Stibora T, et al. Small antibody-like proteins with prescribed ligand specificities derived from the lipocalin fold. Proc Natl Acad Sci U S A 1999;96:1898.
17. Stern M, Herrmann R. Overview of monoclonal antibodies in cancer therapy: Present and promise. Crit Rev Oncol Hematol 2005;54:11.
18. Adams GP, Weiner LM. Monoclonal antibody therapy of cancer. Nat Biotechnol 2005;23:1147.
19. Carter PJ. Potent antibody therapeutics by design. Nat Rev Immunol 2006;6:343.
20. Zafir-Lavie I, Michaeli Y, Reiter Y. Novel antibodies as anticancer agents. Oncogene 2007;26:3714.
21. Olafsen T, Wu AM. Antibody vectors for imaging. Semin Nucl Med 2010;40:167.
22. McCabe K, Wu AM. Positive progress in immunoPET-not just a coincidence. Cancer Biother Radiopharm 2010; 25:253.
23. Verel I, Visser GWM, van Dongen GAMS. The promise of immuno-PET in radioimmunotherapy. J Nucl Med 2005; 46(suppl1):164S.
24. van Dongen GAMS, Visser GWM, Lub-de Hooge MN, et al. Immuno-PET: A navigator in monoclonal antibody development and applications. Oncologist 2007;12:1379.
25. Boswell CA, Brechbiel MW. Development of radioimmunotherapeutic and diagnostic antibodies: An insideout view. Nucl Med Biol 2007;34:757.
26. Wu AM, Olafsen T. Antibodies for molecular imaging of cancer. Cancer J 2008;14:191.
27. Nayak TK, Brechbiel MW. Radioimmunoimaging with longer-lived positron-emitting radionuclides: Potentials and challenges. Bioconjug Chem 2009;Jan uary 6: e-pub ahead of print.
28. Holland JP, Williamson MJ, Lewis JS. Unconventional nuclides for radiopharmaceuticals. Mol Imaging 2010;9:1.
29. Reddy S, Robinson MK. Immuno-positron emission tomography in cancer models. Semin Nucl Med 2010;40:182.
30. Perk LR, Visser GWM, Vosjan MJWD, et al. (89)Zr as a PET surrogate radioisotope for scouting biodistribution of the therapeutic radiometals (90)Y and (177)Lu in tumor-bearing nude mice after coupling to the internalizing antibody cetuximab. J Nucl Med 2005;46:1898.
31. Cai W, Chen K, He L, et al. Quantitative PET of EGFR expression in xenograft-bearing mice using 64Cu-labeled cetuximab, a chimeric anti-EGFR monoclonal antibody. Eur J Nucl Med Mol Imaging 2007;34:850.
32. Aerts HJWL, Dubois L, Perk L, et al. Disparity between in vivo EGFR expression and 89Zr-labeled cetuximab uptake assessed with PET. J Nucl Med 2009;50:123.
33. Tolmachev V, Friedman M, Sandström M, et al. Affibody molecules for epidermal growth factor receptor targeting in vivo: Aspects of dimerization and labeling chemistry. J Nucl Med 2009;50:274.
34. Divgi CR, Welt S, Kris M, et al. Phase I and imaging trial of indium 111-labeled anti-epidermal growth factor receptor monoclonal antibody 225 in patients with squamous cell lung carcinoma. J Natl Cancer Inst 1991;83:97.
35. Dijkers EC, Oude Munnink TH, Kosterink JG, et al. Biodistribution of (89)Zr-trastuzumab and PET imaging of HER2-positive lesions in patients with metastatic breast cancer. Clin Pharmacol Ther 2010;87:586.
36. Verel I, Visser GWM, Boellaard R, et al. 89Zr immuno-PET: Comprehensive procedures for the production of 89Zrlabeled monoclonal antibodies. J Nucl Med 2003;44:1271.
37. Holland JP, Sheh Y, Lewis JS. Standardized methods for the production of high specific-activity zirconium-89. Nucl Med Biol 2009;36:729.
38. Tijink BM, Perk LR, Budde M, et al. (124)I-L19-SIP for immuno-PET imaging of tumour vasculature and guidance of (131)I-L19-SIP radioimmunotherapy. Eur J Nucl Med Mol Imaging 2009;36:1235.
39. Perk LR, Stigter-van Walsum M, Visser GWM, et al. Quantitative PET imaging of Met-expressing human cancer xenografts with 89Zr-labelled monoclonal antibody DN30. Eur J Nucl Med Mol Imaging 2008;35:1857.
40. Brouwers A, Verel I, Van Eerd J, et al. PET radioimmunoscintigraphy of renal cell cancer using 89Zr-labeled cG250 monoclonal antibody in nude rats. Cancer Biother Radiopharm 2004;19:155.
41. Hoeben BAW, Kaanders JHAM, Franssen GM. PET imaging of hypoxia with 89Zr-labeled cG250-F(ab0)2 in head and neck tumors. J Nucl Med 2010;51:1076.
42. Perk LR, Visser OJ, Stigter-van Walsum M, et al. Preparation and evaluation of (89)Zr-Zevalin for monitoring of (90)YZevalin biodistribution with positron emission tomography. Eur J Nucl Med Mol Imaging 2006;33:1337.
43. Muylle K, Azerad , Perk LR. Immuno-PET/CT imaging with Zr-89-rituximab as a prelude for radioimmunotherpy with Y-90-rituximab in patients with relapsed CD20? B cell non-Hodkin?s lymphoma. Ann Oncol 2008;19:179.
44. Nagengast WB, de Vries EG, Hospers GA, et al. In vivo VEGF imaging with radiolabeled bevacizumab in a human ovarian tumor xenograft. J Nucl Med 2007;48:1313.
45. Dijkers ECF, Kosterink JGW, Rademaker AP, et al. Development and characterization of clinical-grade 89Zrtrastuzumab for HER2/neu immunoPET imaging. J Nucl Med 2009;50:974.
46. Perk LR, Vosjan MJWD, Visser GWM, et al. p-Isothiocyanatobenzyl- desferrioxamine: A new bifunctional chelate for facile radiolabeling of monoclonal antibodies with zirconium-89 for immuno-PET imaging. Eur J Nucl Med Mol Imaging 2009;37:250.
47. Vosjan MJWD, Perk LR, Visser GWM, et al. Conjugation and radiolabeling of monoclonal antibodies with zirconium-89 for PET imaging using the bifunctional chelate p-isothiocyanatobenzyl-desferrioxamine. Nat Protoc 2010;5:739.
48. Junutula JR, Raab H, Clark S, et al. Site-specific conjugation of a cytotoxic drug to an antibody improves the therapeutic index. Nat Biotechnol 2008;26:925.
49. Tinianow JN, Gill HS, Ogasawara A, et al. Site-specifically 89Zr-labeled monoclonal antibodies for immunoPET. Nucl Med Biol 2010;37:289.
50. Verel I, Visser GWM, Boerman OC, et al. Long-lived positron emitters zirconium-89 and iodine-124 for scouting of therapeutic radioimmunoconjugates with PET. Cancer Biother Radiopharm 2003;18:655.
51. Verel I, Visser GWM, Vosjan MJWD, et al. High-quality 124Ilabelled monoclonal antibodies for use as PET scouting agents prior to 131I-radioimmunotherapy. Eur J Nucl Med Mol Imaging 2004;31:1645.
52. Verel I, Visser GWM, Boellaard R, et al. Quantitative 89Zr immuno-PET for in vivo scouting of 90Y-labeled monoclonal antibodies in xenograft-bearing nude mice. J Nucl Med 2003;44:1663.
53. Rasbridge SA, Gillett CE, Seymour AM, et al. The effects of chemotherapy on morphology, cellular proliferation, apoptosis and oncoprotein expression in primary breast carcinoma. Br J Cancer 1994;70:335.
54. Gancberg D, Di Leo A, Cardoso F, et al. Comparison of HER-2 status between primary breast cancer and corresponding distant metastatic sites. Ann Oncol 2002;13: 1036.
55. Zidan J, Dashkovsky I, Stayerman C, et al. Comparison of HER-2 overexpression in primary breast cancer and metastatic sites and its effect on biological targeting therapy of metastatic disease. Br J Cancer 2005;93:552.
56. Gong Y, Booser DJ, Sneige N. Comparison of HER-2 status determined by fluorescence in situ hybridization in primary and metastatic breast carcinoma. Cancer 2005;103: 1763.
57. de Korte , de Vries EGE, Lub-de Hooge MN, et al. 111Indium-trastuzumab visualises myocardial human epidermal growth factor receptor 2 expression shortly after anthracycline treatment but not during heart failure: A clue to uncover the mechanisms of trastuzumab-related cardiotoxicity. Eur J Cancer 2007;43:2046.
58. Behr TM, Behe M, Wormann B. Trastuzumab and breast cancer. N Engl J Med 2001;345:995.
59. Lewis Phillips GD, Li G, Dugger DL, et al. Targeting HER2-positive breast cancer with trastuzumab-DM1, an antibodycytotoxic drug conjugate. Cancer Res 2008;68:9280.
60. Tijink BM, Buter J, de Bree R, et al. A phase I dose escalation study with anti-CD44v6 bivatuzumab mertansine in patients with incurable squamous cell carcinoma of the head and neck or esophagus. Clin Cancer Res 2006;12:6064.
61. Holland JP, Caldas-Lopes E, Divilov V, et al. Measuring the pharmacodynamic effects of a novel Hsp90 inhibitor on HER2/neu expression in mice using 89Zr-DFO-trastuzumab. PLoS ONE 2010;5:e8859.
62. Oude Munnink TH, Korte , Nagengast WB, et al. (89)Zrtrastuzumab PET visualises HER2 downregulation by the HSP90 inhibitor NVP-AUY922 in a human tumour xenograft. Eur J Cancer 2010;46:678.
63. Niu G, Cai W, Chen K, et al. Non-invasive PET imaging of EGFR degradation induced by a heat shock protein 90 inhibitor. Mol Imaging Biol 2008;10:99.
64. Nagengast WB, de Korte A, Oude Munnink TH, et al. 89Zrbevacizumab PET of early antiangiogenic tumor response to treatment with HSP90 inhibitor NVP-AUY922. J Nucl Med 2010;51:761.
65. Smith-Jones PM, Solit DB, Akhurst T, et al. Imaging the pharmacodynamics of HER2 degradation in response to Hsp90 inhibitors. Nat Biotechnol 2004;22:701.
66. Smith-Jones PM, Solit D, Afroze F, et al. Early tumor response to Hsp90 therapy using HER2 PET: Comparison with 18F-FDG PET. J Nucl Med 2006;47:793.
67. Niu G, Li Z, Cao Q, et al. Monitoring therapeutic response of human ovarian cancer to 17-DG by noninvasive PET imaging with (64)Cu-DOTA-trastuzumab. Eur J Nucl Med Mol Imaging 2009;36:1510.
68. Wilson CB, Snook DE, Dhokia B, et al. Quantitative measurement of monoclonal antibody distribution and blood flow using positron emission tomography and 124iodine in patients with breast cancer. Int J Cancer 1991;47:344.
69. Larson SM, Pentlow KS, Volkow ND, et al. PET scanning of iodine-124-3F9 as an approach to tumor dosimetry during treatment planning for radioimmunotherapy in a child with neuroblastoma. J Nucl Med 1992;33:2020.
70. Zuckier LS, DeNardo GL. Trials and tribulations: Oncological antibody imaging comes to the fore. Semin Nucl Med 1997;27:10.
71. Jayson GC, Zweit J, Jackson A, et al. Molecular imaging and biological evaluation of HuMV833 anti-VEGF antibody: Implications for trial design of antiangiogenic antibodies. J Natl Cancer Inst 2002;94:1484.
72. Divgi CR, Pandit-Taskar N, Jungbluth AA, et al. Preoperative characterisation of clear-cell renal carcinoma using iodine-124-labelled antibody chimeric G250 (124I-cG250) and PET in patients with renal masses: A phase I trial. Lancet Oncol 2007;8:304.
73. Powles T, Ell PJ. Does PET imaging have a role in renal cancers after all? Lancet Oncol 2007;8:279.
74. Bö rjesson PKE, Jauw YWS, Boellaard R, et al. Performance of immuno-positron emission tomography with zirconium-89-labeled chimeric monoclonal antibody U36 in the detection of lymph node metastases in head and neck cancer patients. Clin Cancer Res 2006;12:2133.
75. Zalutsky MR. Potential of immuno-positron emission tomography for tumor imaging and immunotherapy planning. Clin Cancer Res 2006;12:1958.
76. Bö rjesson PKE, Jauw YWS, de Bree R, et al. Radiation dosimetry of 89Zr-labeled chimeric monoclonal antibody U36 as used for immuno-PET in head and neck cancer patients. J Nucl Med 2009;50:1828.
77. Perik PJ, Lub-de Hooge MN, Gietema JA, et al. Indium-111-labeled trastuzumab scintigraphy in patients with human epidermal growth factor receptor 2-positive metastatic breast cancer. J Clin Oncol 2006;24:2276.
78. Oude Munnink TH, Dijkers EC, Netters SJ, et al. Trastuzumab pharmacokinetics influenced by extent HER2 positive tumor load. J Clin Oncol 2010 May 10; e-pub ahead of print.